/
Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. Our software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world.
The business is unprofitable at the operating level (-65.23% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 23.3% YoY with margins expanding 35.6pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$255M
▲ +23.3% YoY
Net Income (TTM)
-$103M
▲ +44.8% YoY
Op. Margin
-64.65%
▲ +35.6pp YoY
ROIC
-29.20%
▲ +1.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$148M
▲ +107.6% YoY
Op. Cash Flow (TTM)
-$145M
▲ +108.8% YoY
Net Debt
-$292M
Net Cash Position
Cash & Equiv.
$399M
5Y CAGR: +18.8%
5Y CAGR: -2.6%
Continue Research